Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

Mmssmm Aug. 11 at 7:43 PM

$QNCX any update??!!

1 · Reply

Mmssmm Aug. 11 at 5:51 PM

$QNCX $RIOT $NKE $BW $NN Could you imagine if the Volume is up to half million or one million QNCX to the moon soon 🔜

0 · Reply

LORAXX Aug. 11 at 5:34 PM

$QNCX With a just a little volume this one moons. 🤑

0 · Reply

Darkryder Aug. 11 at 6:35 AM

$QNCX Anyone know what was discussed in the Oppenheimer meeting and any outcomes? 🤔

0 · Reply

Mmssmm Aug. 10 at 8:04 PM

$QNCX Again the damn low volume killing and preventing the stock to go up FU Dirk Thye you are a loser who destroyed shareholders value Step down you bastard motherfucar You must be in jail

1 · Reply

Mediev21 Aug. 10 at 5:43 PM

$SION this is the biggest drop in US stock history, after $QNCX in Jan 2026.

0 · Reply

Tygalastkings187 Aug. 10 at 2:24 PM

$QNCX soon 100

1 · Reply

ohlookitsbhawna Aug. 10 at 1:18 PM

$QNCX Any thoughts on this?

0 · Reply

_ProfessorGamma Aug. 9 at 1:13 PM

$QNCX The more I look, the better it gets.

0 · Reply

Mmssmm Aug. 8 at 12:42 AM

$QNCX NO MATTER WHAT WE NEED THIS GOING OVER $80 Dirk Thye Curse is OVER

0 · Reply

Quince Therapeutics Registration statement: Registration filing

2026-08-03T18:05:15.000Z - 8 days ago

Quince Therapeutics management to meet with Oppenheimer

2026-07-31T20:50:26.000Z - 11 days ago

Quince Therapeutics registers to sell 15.47M shares of common stock for holders

Jul 31, 2026, 8:00 AM EDT - 11 days ago

Quince Therapeutics Registration statement: Registration filing

Jul 31, 2026, 8:00 AM EDT - 11 days ago

Quince Therapeutics Proxy statement: Proxy filing

2026-07-29T11:35:29.000Z - 13 days ago

Quince Therapeutics initiated with an Outperform at Oppenheimer

Jun 30, 2026, 8:00 AM EDT - 6 weeks ago

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

2026-06-29T23:50:11.000Z - 6 weeks ago

Quince Therapeutics trading halted, news pending

2026-06-24T10:35:33.000Z - 6 weeks ago

Quince Therapeutics initiated with an Outperform at Leerink

2026-06-23T13:39:25.000Z - 7 weeks ago

Quince Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-06-23T10:12:54.000Z - 7 weeks ago

Quince Therapeutics initiated with an Overweight at Cantor Fitzgerald

May 18, 2026, 10:21 AM EDT - 3 months ago

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026, 10:00 AM EDT - 3 months ago

Quince Therapeutics Transcript: Investor update

May 18, 2026, 10:00 AM EDT - 3 months ago

Quince Therapeutics Press release: Investor update

May 18, 2026, 10:00 AM EDT - 3 months ago

Quince Therapeutics Slides: Investor update

2026-05-18T13:41:04.000Z - 3 months ago

Quince Therapeutics announces LAM-001 data

2026-05-18T13:35:06.000Z - 3 months ago

Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed

May 18, 2026, 9:26 AM EDT - 3 months ago

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026, 9:26 AM EDT - 3 months ago

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 17, 2026, 7:00 AM EDT - 3 months ago

Quince Therapeutics Slides: Investor presentation

May 11, 2026, 7:00 AM EDT - 3 months ago

Quince Therapeutics Quarterly report: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Quince Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Quince Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Quince Therapeutics Proxy statement: Proxy filing

2026-04-10T23:53:15.000Z - 4 months ago

Quince Therapeutics trading halted, news pending

Apr 10, 2026, 7:00 AM EDT - 4 months ago

Quince Therapeutics Annual report: Q4 2025

2026-03-30T12:54:26.000Z - 4 months ago

Quince Therapeutics settles $16.4M of debt

Mar 30, 2026, 8:30 AM EDT - 4 months ago

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Feb 9, 2026, 4:05 PM EST - 6 months ago

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Jan 29, 2026, 3:10 PM EST - 6 months ago

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Jan 28, 2026, 4:05 PM EST - 6 months ago

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Dec 15, 2025, 8:00 AM EST - 8 months ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 10, 2025, 4:05 PM EST - 8 months ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Dec 3, 2025, 10:30 AM EST - 8 months ago

Quince Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 9 months ago

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Quince Therapeutics Slides: Investor Presentation

Nov 12, 2025, 4:05 PM EST - 9 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:00 PM EST - 9 months ago

Quince Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

Quince Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:05 PM EST - 9 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Oct 9, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 2, 2025, 10:00 AM EDT - 11 months ago

Quince Therapeutics Transcript: Investor Day 2025

Oct 2, 2025, 10:00 AM EDT - 11 months ago

Quince Therapeutics Slides: FY 2025

Sep 25, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 15, 2025, 7:00 AM EDT - 11 months ago

Quince Therapeutics Slides: Investor Presentation

Sep 11, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 5, 2025, 7:00 AM EDT - 1 year ago

Quince Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 1 year ago

Quince Therapeutics Slides: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Quince Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Quince Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Registration statement: Registration Filing

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Quince Therapeutics Slides: Investor Presentation

Jun 18, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 1 year ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Earnings release: Q1 2025

May 7, 2025, 3:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Mar 24, 2025, 4:00 PM EDT - 1 year ago

Quince Therapeutics Earnings release: Q4 2024

Mar 24, 2025, 4:00 PM EDT - 1 year ago

Quince Therapeutics Annual report: Q4 2024

Feb 12, 2025, 2:00 PM EST - 1 year ago

Quince Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Transcript: Investor Update

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Press release: Investor Update

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Slides: Investor Update

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Jan 5, 2025, 6:00 PM EST - 1 year ago

Quince Therapeutics Slides: Investor Presentation

Dec 18, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Registration statement: Registration Filing

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 6:00 PM EST - 1 year ago

Quince Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 6:00 PM EST - 1 year ago

Quince Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Quince Therapeutics Transcript: The ThinkEquity Conference 2024

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Quince Therapeutics Slides: FY 2024

Oct 29, 2024, 6:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: LD Micro Main Event XVII

Oct 29, 2024, 6:30 PM EDT - 1 year ago

Quince Therapeutics Slides: LD Micro Main Event XVII

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Earnings release: Q2 2024

Jun 25, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 1:30 PM EDT - 2 years ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 1:30 PM EDT - 2 years ago

Quince Therapeutics Slides: The Citizens JMP Life Sciences Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Quarterly report: Q1 2024

May 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Earnings release: Q1 2024

May 6, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Mar 31, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Annual report: Q4 2023

Mar 31, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Earnings release: Q4 2023

Mar 26, 2024, 4:00 PM EDT - 2 years ago

Quince Therapeutics Transcript: Study Update

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Mmssmm Aug. 11 at 7:43 PM

$QNCX any update??!!

1 · Reply

Mmssmm Aug. 11 at 5:51 PM

$QNCX $RIOT $NKE $BW $NN Could you imagine if the Volume is up to half million or one million QNCX to the moon soon 🔜

0 · Reply

LORAXX Aug. 11 at 5:34 PM

$QNCX With a just a little volume this one moons. 🤑

0 · Reply

Darkryder Aug. 11 at 6:35 AM

$QNCX Anyone know what was discussed in the Oppenheimer meeting and any outcomes? 🤔

0 · Reply

Mmssmm Aug. 10 at 8:04 PM

$QNCX Again the damn low volume killing and preventing the stock to go up FU Dirk Thye you are a loser who destroyed shareholders value Step down you bastard motherfucar You must be in jail

1 · Reply

Mediev21 Aug. 10 at 5:43 PM

$SION this is the biggest drop in US stock history, after $QNCX in Jan 2026.

0 · Reply

Tygalastkings187 Aug. 10 at 2:24 PM

$QNCX soon 100

1 · Reply

ohlookitsbhawna Aug. 10 at 1:18 PM

$QNCX Any thoughts on this?

0 · Reply

_ProfessorGamma Aug. 9 at 1:13 PM

$QNCX The more I look, the better it gets.

0 · Reply

Mmssmm Aug. 8 at 12:42 AM

$QNCX NO MATTER WHAT WE NEED THIS GOING OVER $80 Dirk Thye Curse is OVER

0 · Reply

Mmssmm Aug. 8 at 12:38 AM

$QNCX even this stupid application hate this stock It’s $30.66 in ibkr And this shit 💩 apps $28

0 · Reply

Mmssmm Aug. 7 at 8:10 PM

$QNCX $SPCX $SNDK $MB $MI

0 · Reply

jonahn Aug. 7 at 6:59 PM

$SRXH Still holding off for the moment, in meanwhile $QNCX made me some decent gains. Took a small position today $YYAI and still holding starter on $SOAR . SOAR could still dip to low 0.11's still but also can easily start rallying from here towards 0.30 gap

0 · Reply

Mmssmm Aug. 7 at 5:03 PM

$QNCX let’s break the damn wall of $40 OPPENHEIMER TARGET 🎯 PRICE $82 a share Old management is FIRED NEW MANAGEMENT Orpai Team take over Low Free float 974k shares Lifesci LAM-001 $SPCX

0 · Reply

Mmssmm Aug. 7 at 3:04 PM

$QNCX the damn low volume killing the uprising This must be in $60 a share What is wrong with you people If we don’t take an advantage of the ultra low float then when we do it??!! Free Float is 974k shares only

0 · Reply

Suza271 Aug. 6 at 7:25 PM

$QNCX This is obviously being manipulated. But I'm just glad to get my money back. I was down ALOT

3 · Reply

Tygalastkings187 Aug. 6 at 6:41 PM

$QNCX break the wall $30 and double this to $60!!!!!

0 · Reply

Mmssmm Aug. 6 at 5:22 PM

$QNCX break the damn wall of $30

1 · Reply

Mmssmm Aug. 6 at 4:37 PM

$GOOG $GOOGL $QNCX $SPCX $TSLA QNCX MUST GO UP

0 · Reply

Mmssmm Aug. 5 at 4:59 PM

$QNCX $DKNG $UBER $GLD $GME All roads lead to Rome aka “$100 a share” QNCX with new team of Orphai LAM-001 is gold mine

1 · Reply

Mmssmm Aug. 5 at 4:56 PM

$QNCX let’s broke the wall of $30 QNCX GOING PARABOLIC TO $100 a share $SPCX $TSLA $GOOGL $GOOG

0 · Reply

Mmssmm Aug. 5 at 2:51 PM

$QNCX the curse of Dirk Thye is OVER THIS STOCK MUST BE OVER $100 a share $SPCX $ZETA $UBER $GME

0 · Reply

Market Cap	30.72M
Revenue (ttm)	0.00
Net Income (ttm)	-83.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	35,200
Avg Vol	34,028
Day's Range	N/A - N/A
Shares Out	1.02M
Stochastic %K	94%
Beta	1.36
Analysts	Sell
Price Target	$83.00